Transasia Bio-Medicals Ltd. has acquired Calbiotech Group of Companies, USA, through its German subsidiary Erba Mannheim. This is the 14th overseas IVD acquisition by Transasia in the last 8 years. Calbiotech based in Spring Valley, California, is the first company to introduce immunoassay kits in the United States to detect antibodies against Zika virus in human blood. It is also known to develop innovative products for the emerging markets. It has more than 200 products, distributed to more than 60 countries.
With this acquisition, Transasia is all set to strengthen its foray into ELISA and CLIA assays for human and animal research, including specific assays for autoimmune disorders, cancer, and infectious diseases. Over the years, Transasia has been meeting the needs of the emerging markets through innovative and cutting-edge technologies designed and developed at its global, state-of-the-art facilities.